Esperion Therapeutics' GAAP loss for 2021 was $269.108 million, up 87.5% from $143.551 million in the previous year. Revenue decreased 2.9 times to $78.447 million from $227.547 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept